IRMD iRadimed Corporation

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

"I am pleased to announce that in the third quarter of 2023, we not only achieved record revenue of $16.5 million but also demonstrated our continued commitment to profitability with a noteworthy 43% increase in operating income. This ninth consecutive quarter of record revenues was again led by our monitoring business, which grew by 40% over the second quarter of 2023. I am immensely proud of our team’s dedicated efforts in delivering these outstanding results,” said Roger Susi, President and Chief Executive Officer of the Company. “As for our guidance for the remainder of the year, we expect to report revenue of $16.9 million to $17.4 million for the fourth quarter, GAAP diluted earnings per share of $0.35 to $0.38 and non-GAAP diluted earnings per share of $0.38 to $0.41. For the full-year 2023 financial guidance, we expect revenue of $65.0 million to $65.5 million and raise our guidance for GAAP diluted earnings per share to $1.34 to $1.37 and non-GAAP diluted earnings per share to $1.48 to $1.51,” added Mr. Susi.

Three Months Ended September 30, 2023

For the third quarter ended September 30, 2023, the Company reported over 23% year-over-year revenue growth to $16.5 million compared to $13.4 million for the third quarter of 2022. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 per diluted share for the third quarter of 2022.

Non-GAAP net income was $5.5 million, or $0.43 per diluted share, for the quarter ended September 30, 2023, and excludes $0.4 million of stock compensation expense, net of tax expense. Non-GAAP net income for the quarter ended September 30, 2022, was $3.7 million, or $0.29 per diluted share, and excludes $0.3 million of stock compensation expense, net of tax.

Nine Months Ended September 30, 2023

For the nine months ended September 30, 2023, the Company reported revenue of $48.1 million compared to $38.4 million for the same period of 2022. Net income was $12.7 million, or $0.99 per diluted share, compared to $9.2 million, or $0.72 per diluted share for the same period of 2022.

Non-GAAP net income was $14.0 million, or $1.1 per diluted share, for the nine months ended September 30, 2023, and excludes $1.3 million of stock compensation expense, net of tax expense. Non-GAAP net income for the nine months ended September 30, 2022, was $9.9 million, or $0.78 per diluted share, and excludes $0.7 million of stock compensation expense, net of tax.

Revenue Information:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
	(unaudited)						(unaudited)
Devices:
MRI Compatible IV Infusion Pump Systems	$	3,905,520		$	3,866,535		$	13,966,905		$	11,001,490
MRI Compatible Patient Vital Signs Monitoring Systems		7,738,549			5,519,045			18,564,085			15,635,415
Ferro Magnetic Detection Systems		138,760			62,982			619,539			62,982
Total Devices revenue		11,782,829			9,448,562			33,150,529			26,699,887
Disposables, services, and other		4,213,666			3,410,015			13,464,278			10,158,922
Amortization of extended warranty agreements		508,145			548,695			1,495,313			1,580,742
Total revenue	$	16,504,640		$	13,407,272		$	48,110,120		$	38,439,551

For the third quarter of 2023, domestic sales were 84.5 percent of total revenue, compared to 80.6 percent for the third quarter of 2022. The gross profit margin was 77.8 percent for the third quarter of 2023, compared to 78.6 percent for the third quarter of 2022.

For the nine months ended September 30, 2023, domestic sales were 80.8 percent of total revenue, compared to 82.2 percent for the nine months ended September 30, 2022. The gross profit margin was 76.4 percent for nine months ended September 30, 2023, compared to 78.2 percent for the same period in 2022.

Cash Flow from Operations

For the three months ended September 30, 2023, cash flow from operations was $3.5 million, compared to $2.4 million for the same period in 2022.

For the nine months ended September 30, 2023, cash flow from operations was $9.6 million, compared to $7.0 million for the same period in 2022.

Financial Guidance

For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.

For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.

The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be approximately $1.7 million and $0.4 million for the full year and fourth quarter 2023, respectively.

Use of non-GAAP Financial Measures

The Company believes using non-GAAP net income, free cash flow, and infrequent income tax items is helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with U.S. GAAP.

We calculate non-GAAP net income as net income excluding:

(1) Stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period;

(2) Operating expenses, net of tax, that we believe are not indicative of the Company’s ongoing core operating performance and;

(3) Infrequent tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes.

We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for the development of internal software and purchases of property and equipment.

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our shareholders through various means.

Our non-GAAP financial measures are important tools for financial and operational decision-making and for evaluating our ongoing core operating results.

A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of cash flows. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with U.S. GAAP and are not indicative of net income or cash provided by operating activities.

Conference Call

Iradimed has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today, November 3, 2023. Individuals interested in listening to the conference call may do so by registering here, https://register.vevent.com/register/BI128479408327463f9d559a793be4df6a. Once registered a dial-in number, a unique PIN, and instructions will be provided to participants.

The conference call will also be available in real-time via the Internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the call's completion.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices and accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

For more information, please visit www.iradimed.com.

Forward-Looking Statements

This press release contains forward-looking statements (i.e., statements that are not historical facts). Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management’s current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic, including the impact of existing and new variants, and measures taken in response; potential disruptions in our limited supply chain for our products; the Company’s ability to receive FDA 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.

IRADIMED CORPORATIONCONDENSED BALANCE SHEETS
	September 30,			December 31,
	2023			2022
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	46,745,124		$	57,960,864
Total current assets		71,931,224			77,489,671
Property and equipment, net		8,887,884			2,399,812
Total assets	$	87,406,096		$	85,513,747
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Deferred revenue	$	1,924,133		$	3,373,122
Total current liabilities		7,882,108			8,553,743
Total liabilities		12,838,096			11,840,760
Stockholders’ equity:
Total stockholders’ equity		74,568,000			73,672,987
Total liabilities and stockholders’ equity	$	87,406,096		$	85,513,747

IRADIMED CORPORATIONCONDENSED STATEMENTS OF OPERATIONS(Unaudited)
	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
Revenue	$	16,504,640		$	13,407,272		$	48,110,120		$	38,439,551
Cost of revenue		3,667,256			2,864,534			11,364,791			8,377,526
Gross profit		12,837,384			10,542,738			36,745,329			30,062,025
Operating expenses:
General and administrative		3,615,020			2,881,590			10,848,611			8,000,335
Sales and marketing		2,864,469			3,037,209			8,812,872			9,014,553
Research and development		452,555			491,643			2,208,221			1,673,337
Total operating expenses		6,932,044			6,410,442			21,869,704			18,688,225
Income from operations		5,905,340			4,132,296			14,875,625			11,373,800
Other income, net		503,192			105,183			1,180,988			103,371
Income before provision for income taxes		6,408,532			4,237,479			16,056,613			11,477,171
Provision for income tax expense		1,341,352			810,375			3,403,523			2,322,301
Net income	$	5,067,180		$	3,427,104		$	12,653,090		$	9,154,870
Net income per share:
Basic	$	0.40		$	0.27		$	1.00		$	0.73
Diluted	$	0.40		$	0.27		$	0.99		$	0.72
Weighted average shares outstanding:
Basic		12,602,581			12,564,636			12,597,250			12,559,465
Diluted		12,735,837			12,631,129			12,716,988			12,637,325

IRADIMED CORPORATIONCONDENSED STATEMENTS OF CASH FLOWS(Unaudited)
		Nine Months Ended
		September 30,
		2023				2022
Operating activities:
Net income		$	12,653,090			$	9,154,870
Adjustments to reconcile net income to net cash provided by operating activities:
Change in allowance for doubtful accounts			136,830				56,118
Change in provision for excess and obsolete inventory			219,928				29,227
Depreciation and amortization			559,805				1,363,578
Loss (Gain) on disposal of property and equipment			12,535				(3,000	)
Stock-based compensation			1,635,845				967,551
Deferred income taxes, net			(1,102,866	)			(227,133	)
Loss on maturities of investments			—				(8,025	)
Changes in operating assets and liabilities:
Accounts receivable			343,054				(5,570,783	)
Inventory			(6,130,592	)			(903,792	)
Prepaid expenses and other current assets			(40,055	)			(306,031	)
Other assets			418,274				6,660
Accounts payable			519,648				37,338
Accrued payroll and benefits			(581,699	)			(464,788	)
Other accrued taxes			(18,696	)			3,395
Warranty reserve			16,274				(13,593	)
Deferred revenue			407,064				(452,822	)
Other current liabilities			250,000				(9,508	)
Prepaid income taxes			254,093				3,344,605
Net cash provided by operating activities			9,552,532				7,003,867
Investing activities:
Proceeds from maturities of investments			—				500,000
Purchases of property and equipment			(6,908,607	)			(564,883	)
Capitalized intangible assets			(465,744	)			(838,438	)
Net cash used in investing activities			(7,374,351	)			(903,321	)
Financing activities:
Dividends paid			(13,222,907	)			(12,559,127	)
Proceeds from exercises of stock options			7,341				146,707
Taxes paid related to the net share settlement of equity awards			(178,355	)			(95,523	)
Net cash used in financing activities			(13,393,921	)			(12,507,943	)
Net decrease in cash and cash equivalents			(11,215,740	)			(6,407,398	)
Cash and cash equivalents, beginning of period			57,960,864				61,999,550
Cash and cash equivalents, end of period		$	46,745,124			$	55,592,152
Supplemental disclosure of cash flow information:
Cash paid for income taxes		$	4,136,152			$	757,137
ROU asset recognized in exchange for new lease obligation		$	227,983			$	—
Operating and short-term lease payments recorded within cash flow provided by operating activities		$	492,528			$	364,825

IRADIMED CORPORATIONRECONCILIATION OF NON-GAAP FINANCIAL MEASURES (Unaudited)
Non-GAAP Net Income and Diluted EPS
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2023			2022			2023			2022
Net income		$	5,067,180		$	3,427,104		$	12,653,090		$	9,154,870
Excluding:
Stock-based compensation expense, net of tax expense			416,354			295,284			1,276,051			726,631
Non-GAAP net income		$	5,483,534		$	3,722,388		$	13,929,141		$	9,881,501
Weighted-average shares outstanding – diluted			12,735,837			12,631,129			12,716,988			12,637,325
Non-GAAP net income per share – diluted		$	0.43		$	0.29		$	1.10		$	0.78

Free Cash Flow
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
Net cash provided by operating activities	$	1,392,684		$	3,938,458		$	9,552,532		$	7,003,865
Less:
Capital Expenditures		439,023			556,189			7,374,351	1		1,403,321
Free cash flow	$	953,661		$	3,382,269		$	2,178,181		$	5,600,544
1Capital expenditures include the land acquisition of $6.2 million

Media Contact:IRADIMED CORPORATION(407) 677-8022InvestorRelations@iradimed.com